Brain Imaging in Children With Immune-Related Brain Conditions Such as Multiple Sclerosis

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 2 to 16 years with an immune-mediated brain disease, such as autoimmune encephalitis, ADEM or multiple sclerosis. It also looks for children with a non-immune brain disease, such as stroke.

Age

2 to 16 years (2 years to 15 years 11 months for non-immune brain disease)

Sex

All sexes can join.

Disease stage

A diagnosis of an immune-mediated neurological disease (for example autoimmune encephalitis, acute disseminated encephalomyelitis, multiple sclerosis) or a non-immune neurological disease (for example stroke).

Main reasons for not taking part

• Metal in the body or another reason that rules out MRI scanning at IHN
• A child who usually needs sedation for clinical MRI scans
• The participant does not agree to take part

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 2 and 16 years old?YesNo

What the trial wants to find out

Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.

The group in the trial

• Cross-sectional - participants who have had a neuroimmunological condition over 18 months agoTreatment being tested

  Longitudinal - participants who are within 9 months of disease

  Treatment: OPM- Magnetoencephalography